Bisphosphonates: A practical guide

Current Opinion in Orthopaedics

Volumn 15, Issue 5, 2004, Pages 376-377

  Bukata, Susan V ^a   Healey, John H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DIPHENHYDRAMINE; PAMIDRONIC ACID; PARACETAMOL; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE ATROPHY; BONE DENSITY; BONE GROWTH; BONE METASTASIS; BONE MINERAL; BONE PAIN; CLINICAL TRIAL; CREATININE CLEARANCE; DIGESTIVE SYSTEM ULCER; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; EDITORIAL; FEVER; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GASTRITIS; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; KIDNEY FAILURE; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REFLUX ESOPHAGITIS; URINARY EXCRETION; VERTEBRA FRACTURE;

EID: 4544353902     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bco.0000141919.24040.91     Document Type: Editorial

References (8)

1. Cauley JA, Robbins J, Chen Z, et al.: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290:1729-1738. A landmark study that not only demonstrated the increased risk of stroke, pulmonary embolus, and breast cancer from estrogen and progesterone therapy, but also the clear evidence that this therapy reduced the risk of fracture in the treated population; includes discussion of many of the major endpoints of the study.
2. Solomon CG: Bisphosphonates and Osteoporosis. NEJM 2002; 346:642.
3. Lin JT, Lane JM: Bisphosphonates. JAAOS 2003; 11:1-4. Comprehensive article reviewing the clinical uses of bisphosphonates; includes discussion of pharmacologic action of the various generations of bisphosphonates, the associated side effects, as well as cost of bisphosphonates available in the United States.
4. Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11:83-91.
5. Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. NEJM 2002; 346:653-661.
6. Chang JT, Green L, Beitz J: Renal Failure with the use of zoledronic acid. NEJM 2003; 349:1676-1679. Review of the adverse events reported to the FDA with the dosing of zoledronic acid over the period from August 2001 to March 2003 that related to renal failure. A reply from the drug manufacturer follows this letter and notes that 72 cases were reported in 430,000 treated patients during this time frame.
7. Bauss F, Russell RG: Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporosis Int 2004; 15:423-433. Review of the animal studies and preclinical trials that validate the efficacy of intermittent dosing of bisphosphonates.
8. Chesnut III CH, Skag A, Christiansen C, et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. JBMR 2004; 19:1241-1249. Randomized, double-blind, placebo controlled clinical trial of the investigational bisphosphonate ibandronate in two oral dosing regimens: 2.5 mg daily or 20mg every other day for 12 doses repeated every 3 months. Both treatment groups showed a significant reduction in new vertebral fractures and increases in spine BMD when compared to placebo at 3 years. No significant difference was noted between the dosing regimens, providing additional evidence that intermittent dosing of bisphosphonates can be as effective as daily dosing.